**Description:**
Access to the latest edition of BNF is vital for healthcare professionals.

Compiled with the advice of clinical experts and continually updated to reflect the latest evidence from credible sources worldwide, this essential reference provides up-to-date guidance on prescribing, dispensing, and administering medicines.

Not only does the BNF include a widely accepted framework for the drug management of common diseases, it also includes details of medicines prescribed in the UK, with special reference to their uses, cautions, contraindications, side-effects and dosage. This allows treatment to be tailored to the individual needs of each patient.

The BNF is updated in print every six months by an expert team of pharmacists; validated by a network of leading clinicians from many spheres of clinical practice; and published under the authority of a Joint Formulary Committee. The BNF reflects current best practice as well as legal and professional guidelines relating to the use of medicines. As a result it is used widely as a touchstone reference, and cited by regulatory bodies and courts as a source of authority.

**Unique Benefits:**
- Used 600,000 times a day, 3 million times a week in the UK alone
- Used in 129 countries throughout the world
- Valued for quality, reliability and independence
- As a point-of-care tool, it is important that it provides practitioners with the most up-to-date information and therefore the latest edition is essential
New content and updates:

- Updated guidance for conditions including anal fissure, coeliac disease, dementia, exocrine pancreatic insufficiency, food allergy, multiple sclerosis and short bowel syndrome. New prescribing guidance for biological and biosimilar medicines.

- New drug monographs alirocumab, blinatumomab, brivaracetam, ceftobiprole, clevidipine, elvitegravir, isavuconazole, nivolumab and panobinostat.

- New safety information about fire risk with paraffin-based skin emollients on dressings and clothing and advice on minimising the risk of infections when being treated with idelalisib.

- Updated guidance on starting routine for oral progestogen-only contraceptives and the use of sodium glucose co-transporter 2 inhibitors as monotherapy for treating type 2 diabetes.

International Scope:
Unlike many other local alternatives, the BNF and BNF for Children (BNFC) are unique in bringing together authoritative, independent guidance on best practice with clinically validated drug information, enabling healthcare professionals to select safe and effective medicines.

Both resources provide essential practical information when treating individuals who have been prescribed medicines from the UK.

Format Availability:
Book: 978 0 85711 276 7 Price: £55.00
Format: 210x148mm

Print subscriptions (2 copies per year):
BNF subscription 1 year £ 90.00
BNF + BNFC subscription 1 year £ 130.00
BNF subscription 2 years £ 170.00
BNF + BNFC subscription 2 years £ 250.00

Online via MedicinesComplete and FormularyComplete:
Fully searchable and updated content available via MedicinesComplete and FormularyComplete.
www.medicinescomplete.com and www.formularycomplete.com

Licensing: BNF can also be used to support the preparation of national formularies in other countries.
For bespoke licensing opportunities contact: sales@medicinescomplete.com

Previous Edition: